View Older Stories View More Recent Stories

Jan 13, 2025 11:14AM Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
Jan 13, 2025 09:09AM AbCellera (ABCL) Expands Collaboration with AbbVie (ABBV) to Develop Novel T-Cell Engagers for Oncology
Jan 13, 2025 08:31AM AbbVie (ABBV) and REGENXBIO (RGNX) Announce Updates on the ABBV-RGX-314 Clinical Program
Jan 10, 2025 08:36AM AbbVie (ABBV) to record $3.5B impairment charge related to the emraclidine
Jan 8, 2025 10:10AM Abbvie (ABBV) PT Lowered to $211 at Truist Securities; 'We Like Longer-term Outlook for ABBV'
Jan 7, 2025 11:00AM TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
Jan 6, 2025 04:07PM AbbVie (ABBV) says Q4 EPS expected to include acquired IPR&D and milestones expense of $1.6 billion
Jan 2, 2025 01:02PM Piper Sandler Highlights NBIX, ITCI, ALKS, AXSM as High Conviction Ideas in Biotechnology
Jan 2, 2025 12:39PM TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
Dec 17, 2024 10:22AM Abbvie (ABBV) PT Raised to $220 at Piper Sandler, Reflecting Estimates Increase for Skyrizi & Rinvoq
Dec 13, 2024 09:15AM AbbVie (ABBV) to Acquire Nimble Therapeutics
Dec 11, 2024 09:44AM Truist: 'Potential Impact of Trump's Nominees on Biopharma'
Dec 11, 2024 09:15AM AbbVie (ABBV) Completes Acquisition of Aliada Therapeutics
Dec 10, 2024 11:00AM This pharma stock is TD Cowen's Best Idea for 2025
Dec 10, 2024 09:05AM TD Cowen Names Abbvie (ABBV) Best Idea for 2025
Dec 9, 2024 12:02PM AbbVie (ABBV): Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-
Dec 9, 2024 08:02AM AbbVie (ABBV) Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Nov 22, 2024 06:19AM Leerink Partners Upgrades Abbvie (ABBV) to Outperform
Nov 19, 2024 11:00AM JPM just added these stocks to its Analyst Focus List - giving one 148% upside
Nov 15, 2024 03:20AM AbbVie (ABBV) call put ratio 1 call to 6.4 puts
Nov 12, 2024 09:08AM Abbvie (ABBV) PT Lowered to $208 at BMO Capital
Nov 11, 2024 08:40AM Bristol-Myers Squibb (BMY) Climbs 10% After AbbVie's Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint
Nov 11, 2024 08:36AM AbbVie (ABBV) Falls 13% After Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint
Nov 11, 2024 08:35AM AbbVie (ABBV) Phase 2 Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint
Oct 31, 2024 08:14AM Abbvie (ABBV) PT Raised to $228 at BMO Capital
Oct 31, 2024 08:02AM AbbVie (ABBV), EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
Oct 30, 2024 07:39AM AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
Oct 29, 2024 11:20AM AbbVie (ABBV) January 185 calls active into quarter results
Oct 28, 2024 08:01AM AbbVie (ABBV) Acquires Aliada Therapeutics
Oct 24, 2024 11:32AM AbbVie (ABBV) and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
Oct 18, 2024 05:50AM Abbvie (ABBV) PT Raised to $195 at BofA Securities
Oct 17, 2024 08:03AM AbbVie (ABBV): U.S. FDA Approves VYALEV for Adults Living with Advanced Parkinson's Disease
Oct 16, 2024 11:00AM This pharma stock could deliver a beat and raise quarter, according to Wells Fargo
Oct 10, 2024 07:06AM Abbvie (ABBV) PT Raised to $215 at Truist Securities
Oct 7, 2024 09:23AM Abbvie (ABBV) PT Raised to $225 at TD Cowen
Oct 3, 2024 04:13PM AbbVie (ABBV) says earnings will include acquired IPR&D and milestones expense of $82 million on a pre-tax basis
Oct 3, 2024 04:09PM Morgan Stanley Reiterates Overweight Rating on Abbvie (ABBV)
Sep 27, 2024 12:17PM AbbVie (ABBV) Submits Biologics License Application to the FDA for Telisotuzumab Vedotin
Sep 26, 2024 12:13PM BMO Capital Reiterates Outperform Rating on Abbvie (ABBV)
Sep 26, 2024 08:00AM AbbVie (ABBV) Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Sep 25, 2024 07:01AM AbbVie (ABBV): New Analysis Demonstrates the Efficacy of RINVOQ in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
Sep 24, 2024 07:42AM Piper Sandler Reiterates Overweight Rating on Abbvie (ABBV)
Sep 20, 2024 07:33AM AbbVie (ABBV) Receives Positive CHMP Opinion for Mirvetuximab Soravtansine for the Treatment of Certain Adult Ovarian Cancer
Sep 17, 2024 02:00PM JPMorgan refreshed its U.S. Analyst Focus List and added these four names
Sep 11, 2024 08:31AM AbbVie's (ABBV) Allergan Aesthetics Launches BOTOX Cosmetic for Masseter Muscle Prominence in Adults in China
Sep 10, 2024 12:23PM Unitedhealth Says It Will Remove Abbvie's (ABBV) Humira From Some U.S. Drug Reimbursement Lists Next Year - Reuters
Sep 6, 2024 10:19AM AbbVie (ABBV) Maintains Quarterly Dividend at $1.55; 3.2% Yield
Sep 6, 2024 09:59AM Deutsche Bank on Abbvie (ABBV): 'IMS/IQVIA data for the week ending 8/30/24 show branded Humira holding at 69.6% share (-0.8% w/w) of Adalimumab scripts'
Sep 3, 2024 05:45AM Deutsche Bank Reiterates Hold Rating on Abbvie (ABBV)
Aug 27, 2024 08:07AM AbbVie (ABBV): SkinMedica Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
View More Recent Stories View Older Stories